New hope for lung transplant patients battling dangerous virus
NCT ID NCT07235683
Summary
This study is testing whether adding a newer antiviral drug (letermovir) to the standard treatment helps clear a common and serious viral infection (CMV) faster in people who have received a lung transplant. The trial will involve 40 participants who have active CMV infection. Researchers will compare the new combination to standard treatment alone to see if it leads to better control of the virus with fewer side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG TRANSPLANT RECIPIENT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University Health Network, Toronto General Hospital
RECRUITINGToronto, Ontario, M5G 2C4, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.